Bayer: Jefferies maintains buy rating after results
(CercleFinance.com) - Jefferies reinstates its "buy" rating on Bayer shares, along with its target price of 64 euros, after the German group reported Q1 adjusted EBITDA that is 14% above the broker's expectations and 13% above the consensus.
It said that at a divisional level, consumer health and agrochemicals exceeded expectations, while pharmaceuticals missed them, and that Bayer confirmed that it was targeting an adjusted EBITDA margin of around 26% for 2022, in line with its own forecast.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
It said that at a divisional level, consumer health and agrochemicals exceeded expectations, while pharmaceuticals missed them, and that Bayer confirmed that it was targeting an adjusted EBITDA margin of around 26% for 2022, in line with its own forecast.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.